SLC5A2 and infective vaginitis: SGLT2 inhibitors may lead to adverse effects including polyuria, vaginal infections, and volume depletion or euglycemic diabetic ketoacidosis; on the other hand, GLP-1 receptor agonists may more commonly lead to gastrointestinal symptoms including vomiting and nausea.